Inclusion Criteria:

- Non-myeloid malignancy

- At least 12 additional weeks of cyclic cytotoxic chemotherapy anticipated regardless
of schedule

- Eastern Cooperative Oncology Group performance status of 0-2

- Hemoglobin concentration of less than 11 g/dL within 24 hours before randomization

- Of legal age at the time written informed consent is obtained

Exclusion Criteria:

- Known history of seizure disorder

- Known primary hematologic disorder, which could cause anemia, other than a
non-myeloid malignancy

- Unstable or uncontrolled disease/condition, related to or affecting cardiac function

- Clinically significant inflammatory disease

- Inadequate renal and/or liver function

- Known positive HIV test

- Previously suspected of or confirmed to have neutralizing antibodies to rHuEPO

- Received more than 2 red blood cell (RBC) transfusions within 4 weeks before
randomization or any RBC transfusion within 14 days before randomization, or any
planned RBC transfusion between randomization and study day 1

- Received any erythropoietic therapy within 4 weeks before randomization or any
planned erythropoietic therapy between randomization and study day 1

- Other investigational procedures

- Subject is currently enrolled in or less than 30 days since receipt of any
investigational drug or device that is not approved by the applicable regulatory
authority

- Pregnant or breast feeding

- Not using adequate contraceptive precautions

- Known sensitivity to any of the products to be administered during dosing

- Previously randomized in this study

- Concerns for subject's compliance with protocol procedures